Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Y box binding protein 1 (YB-1) is implicated in tumor progression and treatment resistance (TR).
• Ovarian cancer (OC) remains a significant health challenge with limited treatment options for resistant cases.

Purpose of the Study:

• To investigate the efficacy of a novel YB-1 inhibitor, SU056, in preclinical models of ovarian cancer.
• To elucidate the molecular mechanisms underlying SU056's anti-cancer effects and its potential to overcome treatment resistance.

Main Methods:

• In vitro studies using ovarian cancer cell lines to assess SU056's effects on cell proliferation, apoptosis, and cell cycle.
• Proteomic analysis to identify pathways affected by SU056 treatment.
• In vivo studies in mouse models to evaluate SU056's efficacy alone and in combination with paclitaxel.
• Mechanistic studies to assess drug efflux, multidrug resistance, and neurotoxicity.

Main Results:

• SU056 potently inhibited ovarian cancer cell proliferation, induced apoptosis, and caused G1 cell cycle arrest.
• Proteomic analysis revealed enrichment of apoptosis and RNA degradation pathways, with downregulation of the spliceosome pathway.
• In vivo, SU056 demonstrated independent tumor growth inhibition and synergistic effects with paclitaxel, without observable liver toxicity.
• SU056 inhibited drug efflux and multidrug resistance 1, and exhibited lower neurotoxicity compared to etoposide.

Conclusions:

• YB-1 inhibition by SU056 is a promising strategy for reducing ovarian cancer progression.
• SU056 demonstrates potential in antagonizing treatment resistance and decreasing patient mortality.
• SU056 offers a favorable safety profile with reduced neurotoxicity, suggesting its clinical utility.